Multiple Myeloma Clinical Trials

A listing of 208 Multiple Myeloma clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas.

Home

All Conditions

Multiple Myeloma

Show Filters

Match to Clinical Trials

Access to cutting-edge treatments

Latest clinical trials

Find trials in your area

Start Matching

Filter by Age

There are currently 208 active clinical trials seeking participants for Multiple Myeloma research studies. The states with the highest number of trials for Autism participants are California, New York, Ohio and Texas.

Featured Trial

Major Depressive Disorder Clinical Study

Recruiting

Is depression weighing you down? Local major depressive disorder clinical studies are now enrolling participants in the area. Participating in research studies helps contribute to the advancement of future medicine and treatment options. There is no obligation to take part and health insurance is not required.

Conditions:

Major Depressive Disorder

Major Depression

Major Depressive Episode

Major Depressive Disorder (MDD)

Major Depressive Disorders

Learn More

Featured Trial

Hyperacusis Activities Treatment-Online Study

Recruiting

Are you experiencing hyperacusis? If so, we are recruiting adults with hyperacusis to complete a clinical trial supported by the National Institutes of Health. The study involves participating in a remote counseling program and sound therapy trial for hyperacusis, Hyperacusis Activities Treatment-Online.

Conditions:

Hyperacusis

Tinnitus

Hearing Loss

Learn More

Ohio State University Multiple Myeloma and Amyloidosis Data Registry and Sample Resource

NCT01408225

Recruiting

The investigators are researching patients with diseases of their plasma cells in order to improve their quality and length of life. The investigators have created a database of patient information, blood samples, and bone marrow tissue in order to achieve the following three goals: Surveillance: The investigators want to track what treatments patients get or don't get, how effective they are, how they feel, what complications they suffer, how long they stay in remission, and how long they live... Read More

Gender:

All

Ages:

18 years and above

Trial Updated:

10/11/2023

Locations: Ohio State University Medical Center, Columbus, Ohio

Conditions: Plasma Cell Dyscrasias, Monoclonal Gammopathy of Undetermined Significance, AL Amyloidosis, Multiple Myeloma

Learn More ›

Safety, Efficacy, and Pharmacokinetics of Continuous Subcutaneous Lenalidomide in Multiple Myeloma (MM)

NCT06087653

Recruiting

Primary Objective • Assess the safety and tolerability of low-dose lenalidomide administered by continuous subcutaneous (SC) infusion (STAR-LLD) in combination with dexamethasone and a proteasome inhibitor (PI). Secondary Objectives To assess the immunologic activity of natural killer (NK) cells and T cells for innate and humoral immunity. To establish the pharmacokinetic (PK) profile of STAR-LLD at a defined infusion rate targeting steady-state blood concentrations. To determine pharmacodyna... Read More

Gender:

All

Ages:

18 years and above

Trial Updated:

10/11/2023

Locations: Gabrail Cancer & Research Center, Canton, Ohio

Conditions: Multiple Myeloma

Learn More ›

Early Detection of Multiple Myeloma to Fight Cancer Disparities: A Screening and Patient Navigation Program

NCT05831358

Recruiting

This project will pilot the expansion of the existing Taussig Outreach Program's community outreach and patient navigation model to study the multiple myeloma (MM) screening program. This involves analyzing community reception, screening program methods, reasons patients decided to participate, reasons patients declined participation, and participant views and attitudes. This study also aims to gauge the current and general understanding of MM. This study seeks to recruit participants in the pil... Read More

Gender:

All

Ages:

50 years and above

Trial Updated:

08/15/2023

Locations: Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio

Conditions: Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma

Learn More ›

Real World Treatment Experience of Patients With Breast, Lung, or GI Cancer or Multiple Myeloma Using Remote Symptom Monitoring

NCT05587972

Recruiting

The Carevive registry collects patient characteristics, patient symptoms, and treatment experience data from patients receiving cancer treatment for breast, lung, GI or multiple myeloma. For this study, a core set of variables is collected on each patient in the Carevive platform. Patients will complete a baseline survey in person using a secured device or remotely using their own electronic device in a location of their choice. Weekly electronic Patient Reported Outcome surveys are collected fr... Read More

Gender:

All

Ages:

18 years and above

Trial Updated:

10/18/2022

Locations: Cleveland Clinic, Cleveland, Ohio

Conditions: Breast Cancer, Lung Cancer, Gastrointestinal Cancer, Multiple Myeloma

Learn More ›

Collection of Tissue Samples for Cancer Research

NCT00900198

Recruiting

Background: -Patients who are being evaluated and/or treated at the NIH Clinical Center and adult patients at participating sites will be entered onto this tissue procurement protocol for collection of tissue specimens. Objectives: To obtain samples from adult and pediatric patients for research purposes from tests and procedures that are done as required by the primary research protocol(s) to which a patient is enrolled or as part of their standard-of-care treatment. To obtain samples for research purposes from non-surgical procedures, such as percutaneous biopsies, performed for the sole purpose of obtaining tissue specimens or biological fluids for this protocol. Eligibility: -Adult patients (18 years of age and older) and pediatric patients (younger than 18 years of age) who are being evaluated for and/or treated for cancer at the NIH Clinical Center participating sites. Design: This is a multicenter tissue procurement protocol with NCI as the coordinating center. For adult patients: specimens for research purposes, as outlined in this protocol, will be obtained from tests and procedures that are done as required by the primary research protocols to which a patient is enrolled or as part of their standard-of-care treatment. Non-surgical procedures, such as percutaneous biopsies, may also be performed for the sole purpose of obtaining tissue specimens or biological fluids for this protocol. Tissues and biological fluids to be procured may include but are not limited to blood, serum, urine, tumor tissue, normal tissue, pleural fluid, CSF, saliva, bronchial alveolar lavage (BAL), circulating tumor cells, hair follicles, and bone marrow. These specimens will be stored with unique identifiers and used to perform only those research studies that are outlined in this protocol. For pediatric patients: tumor biopsy/resection tissue used for pediatric preclinical model development will only be from tissue already being obtained as part of a procedure necessary for the patient s clinical care or as part of a primary research protocol; blood specimens will be collected as part of a blood collection already scheduled for the patient s clinical care or as part of the planned pre-procedure bloodwork; volumes collected will not exceed institutional research limits. Given the risks associated with any invasive procedure, such as tumor biopsy, the procedure will be discussed in detail with the patients and their parents/guardian (as indicated), including the side effects, prior to obtaining a separate consent for each procedure. A separate consent will not be signed prior to obtaining samples by minimally invasive measures, such as venipuncture. This study has two separate consent forms at the NIH Clinical Center: one for adult patients to donate specimens for ongoing research on assay development and studies of molecular pathways, and one for adult and age-appropriate pediatric patients to donate samples for the generation of preclinical models. The study also has consent form templates for adult and pediatric patients at participating sites to donate specimens to create preclinical models. Patients may remain on study for the duration of their consent or completion of the planned procedure, whichever comes first. Read Less

Gender:

All

Ages:

2 months and above

Trial Updated:

05/02/2024

Locations: UC Davis, Sacramento, California +16 locations

Conditions: Neoplasms, Lymphomas, Multiple Myeloma, Myelodysplastic Syndrome

Learn More ›

Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer

NCT03412877

Recruiting

Background: A person s tumor is studied for mutations. When cells are found that can attack the mutation in a person s tumor, the genes from those cells are studied to find the parts that make the attack possible. White blood cells are then taken from the person s body, and the gene transfer occurs in a laboratory. A type of virus is used to transfer the genes that make those white blood cells able to attack the mutation in the tumor. The gene transfer therapy is the return of those white blood cells back to the person. Objective: To see if gene transfer therapy of white blood cells can shrink tumors. Eligibility: People with certain metastatic cancer for which standard treatments have not worked. Design: Participants may complete screening under another protocol. Screening includes: Getting tumor cells from a previous procedure Medical history Physical exam Scans Blood, urine, heart, and lung tests The study has 8 stages: Screening tests repeated over 1-2 weeks. Participants will have leukapheresis: Blood is removed by a needle in one arm. A machine removes white blood cells. The rest of the blood is returned by a needle in the other arm. Care at home over approximately 12 weeks. Stopping therapy for 4-6 weeks while their cells are changed in a lab. Hospital stay approximately 3-4 weeks for treatment. An IV catheter will be placed in the chest to administer drugs. Patients on Arm 2 of the study will receive the first dose of pembrolizumab while in the hospital. Three additional doses will be given after the cell infusion 3 weeks apart. Receiving changed cells by catheter. Then getting a drug over 1-5 days to help the cells live longer. Recover in the hospital for 1-2 weeks. Participants will get drugs and have blood and urine tests. Participants will take an antibiotic and maybe an antiviral for at least 6 months after treatment. They will have repeat screening tests at visits every few months for the first year, every 6 months for the second year, then as determined. Read Less

Gender:

All

Ages:

Between 18 years and 72 years

Trial Updated:

05/02/2024

Locations: National Institutes of Health Clinical Center, Bethesda, Maryland

Conditions: Non-Small Cell Lung Cancer, Ovarian Cancer, Breast Cancer, Endocrine Tumors, Neuroendocrine Tumors, Gastrointestinal/Genitourinary Cancers, Multiple Myeloma

Learn More ›

Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

NCT04975997

Recruiting

This is a multicenter, two-stage, randomized, controlled, open-label, Phase 3 study comparing the efficacy and safety of iberdomide in combination with dexamethasone and daratumumab (IberDd) versus daratumumab, bortezomib, and dexamethasone (DVd) in participants with relapsed or refractory multiple myeloma (RRMM).

Gender:

All

Ages:

18 years and above

Trial Updated:

05/02/2024

Locations: Genesis cancer and Blood Institute (GCBI) - Sarah Cannon, Hot Springs, Arkansas +257 locations

Genesis cancer and Blood Institute (GCBI) - Sarah Cannon, Hot Springs, Arkansas

Local Institution - 683, Corona, California

Compassionate Cancer Care Medical Group Inc., Fountain Valley, California

USC Norris Comprehensive Cancer Center, Los Angeles, California

Local Institution - 684, Newport, California

Yale University School Of Medicine, New Haven, Connecticut

Local Institution - 029, Fort Myers, Florida

Baptist MD Anderson Cancer Center, Jacksonville, Florida

Local Institution - 028, Saint Petersburg, Florida

BRCR Global, Tamarac, Florida

Local Institution - 034, West Palm Beach, Florida

Emory University School of Medicine, Atlanta, Georgia

Local Institution - 040, Louisville, Kentucky

Christus St Francis Cabrini Hospital, Alexandria, Louisiana

Local Institution - 682, Baton Rouge, Louisiana

Local Institution - 027, Baton Rouge, Louisiana

Center For Cancer And Blood Disorders, Bethesda, Maryland

Local Institution - 010, Boston, Massachusetts

University of Massachusetts Memorial Medical Center, Worcester, Massachusetts

HCA Midwest Health, Kansas City, Missouri

St. Vincent Frontier Cancer Center, Billings, Montana

Local Institution - 015, Summit, New Jersey

Local Institution - 042, Bay Shore, New York

Duke University Hospital, Durham, North Carolina

TriHealth, Good Samaritan Hospital, Cincinnati, Ohio

MetroHealth Medical Center - Main Campus, Cleveland, Ohio

Cleveland Clinic - Taussig Cancer Institute, Cleveland, Ohio

Ohio Health Corporation, Columbus, Ohio

Oklahoma Cancer Specialists and Research Institute, Tulsa, Oklahoma

Oregon Health and Science University, Portland, Oregon

Penn State Hershey Cancer Institute, Hershey, Pennsylvania

Tennessee Oncology, Chattanooga, Tennessee

Sarah Cannon Research Institute (SCRI), Nashville, Tennessee

University Of Wisconsin, Madison, Wisconsin

Local Institution - 080, Ciudad Autanoma De Buenos Aires, Buenos Aires

Local Institution - 083, Villa Elisa, Buenos Aires

Local Institution - 813, Birtinya, Queensland

The Townsville Hospital, Douglas, Queensland

Royal Adelaide Hospital, Adelaide, South Australia

Flinders Medical Centre, Dept Of Oncology, Bedford Park, South Australia

Monash Medical Centre, Clayton, Victoria

Epworth Hospital, East Melbourne, Victoria

The Alfred Hospital, Melbourne, Victoria

Fiona Stanley Hospital, Murdoch, Western Australia

Perth Blood Institute, West Perth, Western Australia

Royal Prince Alfred Hospital, Camperdown, Not set

St Vincent's Hospital Melbourne, Fitzroy, Not set

The Canberra Hospital, Garran, Not set

Medical University of Graz, Graz, Not set

Krankenhaus Der Barmherzigen Schwestern Linz, Linz, Not set

Universitatsklinik der PMU, Salzburg, Not set

University Hospital St. Poelten, St Polten, Not set

Medizinische Universität Wien, Vienna, Not set

Local Institution - 151, Wien, Not set

Local Institution - 157, Wien, Not set

AZ Sint-Jan AV Brugge, Brugge, Not set

Cliniques Universitaires Saint-Luc, Bruxelles, Not set

Local Institution - 170, Liege, Not set

Local Institution - 056, Curitiba, Parana

Local Institution - 058, Porto Alegre, RIO Grande DO SUL

Local Institution - 050, Porto Alegre, RS

Local Institution - 054, Jau, SAO Paulo

Local Institution - 051, Barretos, São Paulo

Local Institution - 053, Rio de Janeiro, Not set

Local Institution - 055, Sao Paulo, Not set

Local Institution - 057, Sao Paulo, Not set

Local Institution - 052, Sao Paulo, Not set

Local Institution - 111, Calgary, Alberta

Local Institution - 103, Edmonton, Alberta

BC Cancer Agency, Fraser Valley Center, Surrey, British Columbia

Local Institution - 104, Saint John, New Brunswick

Memorial University of NewfoundlandDr. H Bliss Murphy Cancer Center, St John's, Newfoundland and Labrador

Queen Elizabeth Ii Health Sciences Centre, Halifax, Nova Scotia

Local Institution - 109, Ottawa, Quebec

Local Institution - 107, Saskatoon, Saskatchewan

CHU de Quebec-Universite Laval, Quebec, Not set

The Third Xiangya Hospital of Central South University, Changsha, Hunan

The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi

Local Institution - 143, Xian, Shaanxi

Local Institution - 142, Shanghai, Shanghai

Shanxi Bethune Hospital, Taiyuan, Shanxi

Local Institution - 144, Wenzhou, Zhejiang

Beijing Boren Hospital, Beijing, Not set

Peking University Third Hospital, Beijing, Not set

Beijing Peking Union Medical College Hospital, Beijing, Not set

First Hospital of Jilin University, Changchun, Not set

Beijing Chaoyang Hospital Capital Medical University, Chaoyang District, Not set

Guangdong General Hospital, Guangzhou, Not set

Sun Yat-sen University Cancer Center, Guangzhou, Not set

The First Affiliated Hospital of Medical School of Zhejiang University, Hangzhou City, Not set

The First Affiliated Hospital of Medical School of Zhejiang University, Hangzhou, Zhejiang, Not set

The First Affiliated Hospital Of Harbin Medical University, Harbin, Not set

Jiangsu Province Hospital, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Not set

Ruijin Hospital Shanghai Jiaotong University, Shanghai, Not set

Zhongshan Hospital Fudan University, Shanghai, Not set

Shengjing Hospital Of China Medical University, Shenyang, Not set

The First Affiliated Hospital Of Soochow University, Suzhu, Not set

Institution of Hematology & Hospital of Blood Disease, Chinese Academy of Medical Sciences, Tianjin, Not set

Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, Not set

Xijing Hospital, Xian, Not set

Henan Cancer Hospital, Zhengzhou, Not set

Fakultni nemocnice Brno, Brno, Not set

Fakultni nemocnice Ostrava, Ostrava-Poruba, Not set

Vseobecna Fakultni Nemocnice V Praze, Prague 2, Not set

Aalborg Universitetshospital, Aalborg, Not set

Odense University Hospital, Odense, Not set

Sealand University Hospital, Roskilde, Not set

Helsinki University Central Hospital, Helsinki, Not set

Oulu University Hospital, Oulu, Not set

Turku University Hospital, Turku, Not set

CH Argenteuil Victor Dupouy, Argenteuil, Not set

Centre Hospitalier Departemental de Vendee, La Roche -Sur-Yon - Cedex 9, Not set

CHRU de Lille France, Lille Cedex, Not set

CHU de Nancy - Hopital Brabois- Service d'Hematologie et DE medecine Interne, 7eme etage, Nancy Cedex, Not set

Local Institution - 454, Nantes, Not set

Hopital Saint-Louis, Paris Cedex, Not set

Hopital Saint Antoine, Paris, Not set

Chu Bordeaux, Pessac, Not set

Centre Henri Becquerel, Rouen, Not set

Institut Universitaire du Cancer de Toulouse - Oncopole, Toulouse Cedex 9, Not set

Uniklinik Schleswig-Holstein Kiel, Kiel, Schleswig-Holstein

Klinikum der Johann Wolfgang Goethe Universitat, Frankfurt am Main, Not set

Universitaetsklinik Hamburg - Eppendorf, Hamburg, Not set

Asklepios Altona, Hamburg, Not set

Universitaetsklinikum Heidelberg, Heidelberg, Not set

Universitatsklinikum Schleswig-Holstein, Lubeck, Not set

University General Hospital of Patras, Patras, Achaea

Local Institution - 574, Patra, Achaia

Alexandra General Hospital Of Athens, Athens, Not set

Theagenio Anticancer Hospital of Thessaloniki, Thessaloniki, Not set

Georgios Papanikolaou General Hospital of Thessaloniki, Thessaloniki, Not set

Local Institution - 932, Hyderabad, Andhra Pradesh

M. S. Ramaiah Medical College And Hospital, Bangalore, Karnataka

Local Institution - 934, Ernakulam, Kerala

Local Institution - 933, Mumbai, Maharashtra

Nil Ratan Sircar Medical College and Hospital, Kolkata, West Bengal

Local Institution - 931, Pondicherry, Not set

Cork University Hospital, Cork, Not set

Beaumont Hospital, Dublin 9, Not set

Local Institution - 751, Galway, Not set

Local Institution - 874, Afula, HaZafon

Rambam Medical Center, Haifa, Not set

Hadassah Medical Center, Jerusalem, Not set

Tel Aviv Sourasky Medical Center, Tel Aviv, Not set

Sheba Medical Center - PPDS, Tel Hashomer, Not set

Local Institution - 415, Roma, Lazio

A.O.U. di Bologna Policlinico S.Orsola-Malpighi, Bologna, Not set

Università di Catania- Presidio Ospedaliero Ferrarotto, Catania, Not set

A.O.U. San Martino, Genova, Not set

Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico, Milano, Not set

Local Institution - 407, Milano, Not set

A.O.U. Maggiore della Carit, Novara, Not set

Fondazione Irccs Policlinico San Matteo, Pavia, Not set

Azienda Ospedaliera Universitaria Pisana, Pisa, Not set

Local Institution - 405, Reggio Calabria, Not set

Local Institution - 413, Reggio Emilia, Not set

Azienda Ospedaliera S. Andrea - Università La Sapienza, Roma, Not set

IRCCS Ospedale Casa Sollievo della Sofferenza, San Giovanni Rotondo FG, Not set

Local Institution - 409, Terni, Not set

Azienda Ospedaliero-Universitaria Santa Maria della Misericordia die Udine, Udine, Not set

Matsuyama Red Cross Hospital, Matsuyama, Ehime

Local Institution - 917, Higashi-Ibaraki-gun, Ibaraki

Local Institution - 919, Shimotsuga, Tochigi

Local Institution - 920, Nerima-ku, Tokyo

Local Institution - 918, Shinagawa-ku, Tokyo

University of Yamanashi Hospital, Chuo-shi, Yamanashi

Aomori Prefectural Central Hospital, Aomori, Not set

Chiba Cancer Center, Chiba, Not set

National Hospital Organization Kyushu Medical Center, Fukuoka, Not set

Kameda General Hospital, Kamogawa, Not set

University Hospital,Kyoto Prefectural University of Medicine, Kyoto-City, Not set

Aichi Cancer Center, Nagoya, Not set

Nagoya City University Hospital, Nagoya, Not set

Okayama Medical Center, Okayama, Not set

Kindai University Hospital- Osakasayama Campus, Osaka-Sayama, Not set

Osaka Metropolitan university Hospital, Osaka, Not set

Sapporo Hokuyu Hospital, Sapporo, Not set

Tohoku University Hospital, Sendai, Not set

Japan Red Cross Medical Center, Shibuya-ku, Not set

NTT Medical Center Tokyo, Shinagawa-ku, Tokyo, Not set

Toyohashi Municipal Hospital, Toyohashi, Not set

Kyungpook National University Hospital, Daegu, Not set

National Cancer Center, Gyeonggi-do, Not set

Hwasun Chonnam National University Hospital, Hwasun-gun, Not set

Samsung Medical Center, Seoul, Not set

The Catholic University of Korea Seoul - Saint Mary's Hospital, Seoul, Not set

Severance Hospital, Yonsei University Health System, Seoul, Not set

Seoul National University Hospital, Seoul, Not set

Asan Medical Center, Seoul, Not set

Local Institution - 182, Mexico City, Distrito Federal

Local Institution - 183, Guadalajara, Jalisco

Local Institution - 181, La Raza, Not set

Local Institution - 180, Mexico City, Not set

Albert Schweitzer Ziekenhuis, Dordrecht, Zuid-Holland

Vrije Universiteit Medisch Centrum (Vumc), Amsterdam, Not set

Hagaziekenhuis, Den Haag, Not set

Haukeland University Hospital, Bergen, Not set

Oslo Myeloma Center - PPDS, Oslo, Not set

St. Olav's University Hospital, Trondheim, Not set

Uniwersytecki Szpital Kliniczny w Białymstoku, Bialystok, Podlaskie

Szpital Uniwersytecki W Krakowie, Krakow, Not set

Szpital Specjalistyczny im. Jedrzeja Sniadeckiego w Nowym Saczu, Nowy Sacz, Not set

Szpital Kliniczny im. H.Swiecickiego Uniwersytetu Medycznego im. Karola Marcinkowskiego w Poznaniu, Poznan, Not set

Specjalistyczny Szpital im. dra Alfreda Sokolowskiego, Walbrzych, Not set

Centrum Onkologii-Instytut im.Marii Sklodowskiej-Curie, Warszawa, Not set

Centro Hospital e Universitario de Coimbra, Coimbra, Not set

Instituto Portugues de Oncologia de Lisboa, Francisco Gentil, Lisboa, Not set

Champalimaud Cancer Center, Lisboa, Not set

Ipo Instituto Portugues De Oncologia Porto, Porto, Not set

Centro Hospitalar de Sao Joao, EPE, Porto, Not set

Clinica Universidad de Navarra, Pamplona, Navarra

Hospital de la Santa Creu i Sant Pau, Barcelona, Not set

Hospital Universitario Vall D hebron - PPDS, Barcelona, Not set

Hospital Universitari Germans Trias I Pujol, Barcelona, Not set

Hospital San Pedro de Alcántara, Caceres, Not set

Hospital Universitario Reina Sofia, Cordoba, Not set

Hospital De La Princesa, Madrid, Not set

Clinica Universidad de Navarra-Madrid, Madrid, Not set

Hospital Universitario Ramón y Cajal, Madrid, Not set

Hospital Universitario Fundacion Jimenez Diaz, Madrid, Not set

Hospital Universitario Virgen De La Victoria, Malaga, Not set

Hospital Universitario Virgen de La Arrixaca, Murcia, Not set

Hospital Universitario Central de Asturias, Oviedo, Not set

Hospital Universitario de Salamanca - Complejo Asistencial Universitario de Salamanca, Salamanca, Not set

Hospital Clinico Universitario De Santiago, Santiago de Compostela, Not set

Hospital Universitari i Politecnic La Fe de Valencia, Valencia, Not set

Hospital Universitario Miguel Servet, Zaragoza, Not set

Sodra Alvsborgs Sjukhus Boras, Boras, Not set

Helsingborgs Lasarett, Helsingborg, Not set

Kantonsspital Graubunden, Chur, Not set

Kantonsspital St. GallenBereich OnkologieHamatologie, St. Gallen, Not set

Chang Gung Medical Foundation, Kaohsiung Memorial Hospital, Niao-Sung Hsiang Kaohsiung County, Not set

China Medical University Hospital, Taichung City, Not set

Taichung Veterans General Hospital, Taichung, Not set

National Cheng Kung University Hospital, Tainan, Taiana, Not set

National Taiwan University Hospital, Taipei, Zhongzheng Dist., Not set

Taipei Veterans General Hospital, Taipei, Not set

Chang Gung Medical Foundation, Linkou Memorial Hospital, Taoyuan City, Not set

Liv Hospital Ankara, Kavaklıdere, Ankara

Dr. Abdurrahman Yurtaslan Ankara Onkoloji Egitim ve Arastırma Hastanesi, Yenimahalle, Ankara

Marmara University Pendik Training and Research Hospital, Pendik, Istanbul

Dokuz Eylul University Medical Faculty, Balçova, Izmir

Ege University Medical Faculty, Bornova, Izmir

Ondokuz Mayis Universitesi Tip Fakultesi Hastanesi, Samsun, Kurupelit

Ankara University Medical Faculty, Ankara, Not set

Gazi University Faculty Of Medicine, Gaziantep, Not set

Erciyes University Medical Faculty, Kayseri, Not set

Local Institution - 702, Nottingham, Nottinghamshire

Belfast City Hospital, Belfast Northern Ireland, Not set

University Hospitals Birmingham NHS Foundation Trust - Queen Elizabeth Hospital, Birmingham, Not set

Kent and Canterbury Hospital, Canterbury Kent, Not set

Local Institution - 704, Lancashire Blackpool, Not set

University College London Hospitals NHS Foundation Trust - University College Hospital, London, Not set

Guy's and St Thomas' Hospital - London, London, Not set

Oxford University Hospitals NHS Foundation Trust-Churchill Hospital-Cancer and Haematology Centre, Oxford, Not set

Local Institution - 711, Portsmouth, Not set

The Royal Marsden NHS Foundation Trust, Sutton, Not set

New Cross Hospital, Wolverhampton, Not set

Conditions: Multiple Myeloma

Learn More ›

Evaluating the Uptake and Utility of Clinical Pathways for Newly Diagnosed Patients With Multiple Myeloma

NCT06149910

Recruiting

All4Cure is partnering with community oncology practices participating in the Quality Cancer Care Alliance (QCCA) and Exigent Research to develop a clinical pathway that standardizes the evaluation, treatment and ongoing management of patients with newly diagnosed multiple myeloma who wish to achieve and maintain MRD negativity. This is a longitudinal retrospective study that will collect data from three separate cohorts of patients with newly diagnosed multiple myeloma (NDMM). The cohorts clas... Read More

Gender:

All

Ages:

18 years and above

Trial Updated:

05/02/2024

Locations: All4Cure, Seattle, Washington

Conditions: Multiple Myeloma, Multiple Myeloma Without Mention of Remission

Learn More ›

Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation

NCT02356159

Recruiting

Background: - In allogeneic stem cell transplantation (SCT), stem cells are taken from a donor and given to a recipient. Sometimes the recipient s immune system destroys the donor s cells. Or donor immune cells attack the recipient s tissues, called graft-versus-host disease (GVHD). This is less likely when the recipient and donor have similar human leukocyte antigens (HLA). Researchers want to see if the drug palifermin improves the results of allogeneic SCT from HLA-matched unrelated donors.... Read More

Gender:

All

Ages:

18 years and above

Trial Updated:

05/02/2024

Locations: National Institutes of Health Clinical Center, Bethesda, Maryland +1 locations

Conditions: Myelodysplastic Syndrome, Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma, Acute Leukemia, Multiple Myeloma

Learn More ›

PHE885 CAR-T Therapy in Adult Participants With Relapsed and Refractory Multiple Myeloma

NCT05172596

Recruiting

This is a Phase II study to determine the efficacy and safety of PHE885, a BCMA-directed CAR-T cell therapy, manufactured with a new process. The CAR-T cell therapy will be investigated as a single agent in relapsed and refractory multiple myeloma

Gender:

All

Ages:

18 years and above

Trial Updated:

05/02/2024

Locations: Stanford University ., Palo Alto, California +37 locations

Stanford University ., Palo Alto, California

Emory University School of Medicine/Winship Cancer Institute, Atlanta, Georgia

Dana Farber Cancer Institute Main Site, Boston, Massachusetts

Oregon Health Sciences University ., Portland, Oregon

Thomas Jefferson University ., Philadelphia, Pennsylvania

Fred Hutch Cancer Research, Seattle, Washington

Novartis Investigative Site, VIC, Melbourne

Novartis Investigative Site, Camperdown, New South Wales

Novartis Investigative Site, Salvador, BA

Novartis Investigative Site, Sao Paulo, SP

Novartis Investigative Site, São Paulo, SP

Novartis Investigative Site, Calgary, Alberta

Novartis Investigative Site, Lille, Not set

Novartis Investigative Site, Nantes Cedex 1, Not set

Novartis Investigative Site, Paris 10, Not set

Novartis Investigative Site, Poitiers, Not set

Novartis Investigative Site, Hamburg, Not set

Novartis Investigative Site, Heidelberg, Not set

Novartis Investigative Site, Koeln, Not set

Novartis Investigative Site, Wuerzburg, Not set

Novartis Investigative Site, Thessaloniki, GR

Novartis Investigative Site, Athens, Not set

Novartis Investigative Site, Ramat Gan, Not set

Novartis Investigative Site, Tel Aviv, Not set

Novartis Investigative Site, Bologna, BO

Novartis Investigative Site, Milano, MI

Novartis Investigative Site, Nagoya-city, Aichi

Novartis Investigative Site, Sapporo city, Hokkaido

Novartis Investigative Site, Kyoto-city, Kyoto

Novartis Investigative Site, Sendai city, Miyagi

Novartis Investigative Site, Riyadh, Not set

Novartis Investigative Site, Singapore, Not set

Novartis Investigative Site, Salamanca, Castilla Y Leon

Novartis Investigative Site, Pamplona, Navarra

Novartis Investigative Site, Birmingham, Not set

Novartis Investigative Site, Glasgow, Not set

Novartis Investigative Site, Manchester, Not set

Conditions: Multiple Myeloma

Learn More ›

Phase I/II Open Label Study of Belumosudil Mesylate Alone, and in Combination With Dexamethasone, in Patients With Relapsed/Refractory Multiple Myeloma

NCT06105554

Recruiting

Phase 1 is to find the recommended dose of belumosudil mesylate that can be given to patients with relapsed/refractory MM. Phase 2 is to learn if the dose of belumosudil mesylate found in Phase 1 can help to control the disease.

Gender:

All

Ages:

18 years and above

Trial Updated:

05/01/2024

Locations: M D Anderson Cancer Center, Houston, Texas

Conditions: Multiple Myeloma

Learn More ›

A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation

NCT06399393

Recruiting

The purpose of this study is to compare the efficacy, safety, and tolerability of ide-cel with lenalidomide (LEN) maintenance to that of LEN maintenance alone in adult participants with Newly Diagnosed Multiple Myeloma (NDMM) who have achieved a suboptimal response post autologous stem cell transplantation (ASCT).

Gender:

All

Ages:

18 years and above

Trial Updated:

05/01/2024

Locations: Banner MD Anderson Cancer Center, Gilbert, Arizona +117 locations

Banner MD Anderson Cancer Center, Gilbert, Arizona

Mayo Clinic in Arizona - Scottsdale, Scottsdale, Arizona

UCLA Hematology/Oncology - Westwood (Building 200 Suite 120), Los Angeles, California

University of California, Irvine (UCI) Health - UC Irvine Medical Center, Orange, California

University of California Davis (UC Davis) Comprehensive Cancer Center, Sacramento, California

Colorado Blood Cancer Institute, Denver, Colorado

Yale University School of Medicine, New Haven, Connecticut

Mayo Clinic in Florida, Jacksonville, Florida

AdventHealth Orlando, Orlando, Florida

Moffitt Cancer Center, Tampa, Florida

Winship Cancer Institute, Emory University, Atlanta, Georgia

Northside Hospital, Atlanta, Georgia

Massachusetts General Hospital, Boston, Massachusetts

Boston Medical Center, Boston, Massachusetts

Local Institution - 0123, Ann Arbor, Michigan

Ascension Providence Hospital, Southfield, Michigan

Local Institution - 0119, Minneapolis, Minnesota

Mayo Clinic in Rochester, Minnesota, Rochester, Minnesota

Washington University School of Medicine, Saint Louis, Missouri

Columbia University Irving Medical Center, New York, New York

Novant Health Cancer Institute - Elizabeth, Charlotte, North Carolina

Wake Forest Baptist Health, Winston-Salem, North Carolina

University Hospitals Cleveland Medical Center, Cleveland, Ohio

The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive Cancer Center, Columbus, Ohio

Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania

St. David's South Austin Medical Center, Austin, Texas

UT Southwestern Medical Center, Dallas, Texas

Houston Methodist Hospital, Houston, Texas

University of Texas MD Anderson Cancer Center, Houston, Texas

Local Institution - 0136, Richmond, Virginia

Royal Prince Alfred Hospital, Camperdown, New South Wales

Local Institution - 0005, Brisbane, Queensland

Peter MacCallum Cancer Centre, Melbourne, Victoria

The Alfred Hospital, Melbourne, Victoria

St Vincent's Hospital, Melbourne, Victoria

Fiona Stanley Hospital, Murdoch, Western Australia

Uniklinikum Salzburg, Salzburg, Not set

Medizinische Universität Wien, Wien, Not set

Institut Jules Bordet, Anderlecht, Bruxelles-Capitale, Région De

UZ Brussel, Brussels, Bruxelles-Capitale, Région De

Local Institution - 0133, Edmonton, Alberta

Hamilton Health Sciences-Juravinski Cancer Centre, Hamilton, Ontario

Local Institution - 0134, Montreal, Quebec

Local Institution - 0036, Brno, Brno-město

Local Institution - 0034, Hradec Kralove, Hradec Králové

Local Institution - 0035, Olomouc, Olomoucký Kraj

Local Institution - 0033, Praha 2, Not set

Local Institution - 0070, Odense, Syddanmark

CHU Bordeaux Haut-Leveque, Pessac, Aquitaine

Institut Paoli-Calmettes, Marseille, Bouches-du-Rhône

Hopital Claude Huriez - CHU de Lille, Lille, Nord

Centre Hospitalier Universitaire de Nantes - L' Hopital l'hôtel-Dieu, Nantes, Pays-de-la-Loire

Centre Hospitalier Lyon Sud, Pierre-Bénite, Rhône

Henri Mondor Hospital, Créteil, Val-de-Marne

Gustave Roussy, Villejuif, Val-de-Marne

Local Institution - 0029, Poitiers, Vienne

Hôpital Saint-Louis, Paris, Not set

Institut Universitaire du Cancer Toulouse - Oncopole - CHU de TOULOUSE, Toulouse, Not set

Hôpital Saint Antoine, Paris, Île-de-France

Local Institution - 0072, Heidelberg, Baden-Württemberg

Local Institution - 0078, Ulm, Baden-Württemberg

Local Institution - 0077, Nuremberg, Bayern

Local Institution - 0073, Köln, Nordrhein-Westfalen

Local Institution - 0079, Dresden, Sachsen

Local Institution - 0087, Leipzig, Sachsen

Local Institution - 0075, Kiel, Schleswig-Holstein

Local Institution - 0115, Essen, Not set

Local Institution - 0076, Hamburg, Not set

Local Institution - 0074, Wuerzburg, Not set

University Hospital of Patras, Patras, Achaḯa

Evangelismos General Hospital of Athens, Athens, Attikí

Attikon General University Hospital, Chaidari, Attikí

G. Papanikolaou General Hospital, Thessaloniki, Thessaloníki

Local Institution - 0055, Be'er Sheva, HaDarom

Local Institution - 0058, Petah-Tikva, HaMerkaz

Sheba Medical Center, Ramat Gan, HaMerkaz

Sourasky Medical Center, Tel Aviv, Tell Abīb

Rambam Health Care Campus, Haifa, Not set

Hadassah Medical Center, Jerusalem, Not set

Humanitas, Rozzano, Milano

Local Institution - 0067, Torino, Piemonte

IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico di Sant'Orsola, Bologna, Not set

AOU Policlinico Umberto I, Roma, Not set

Nagoya City University Hospital, Nagoya, Aichi

Hokkaido University Hospital, Sapporo, Hokkaido

Hyogo Medical University Hospital, Nishinomiya, Hyogo

Kanazawa University Hospital, Kanazawa, Ishikawa

Tokai University Hospital, Isehara, Kanagawa

Chiba University Hospital, Chiba, Not set

Local Institution - 0054, Fukuoka, Not set

Okayama University Hospital, Okayama, Not set

Local Institution - 0071, Shimotsuke, Not set

Local Institution - 0050, Tokyo, Not set

Local Institution - 0041, Hwasun Gun, Jeonranamdo

Local Institution - 0039, Seoul, Seoul-teukbyeolsi [Seoul]

Local Institution - 0040, Seoul, Seoul-teukbyeolsi [Seoul]

Local Institution - 0038, Seoul, Seoul-teukbyeolsi [Seoul]

Local Institution - 0043, Seoul, Seoul-teukbyeolsi [Seoul]

Oslo Universitetssykehus Rikshospitalet, Oslo, Not set

Centrum Onkologii Ziemi Lubelskiej, Lublin, Lubelskie

Samodzielny Publiczny Centralny Szpital Kliniczny w Warszawie, Warsaw, Mazowieckie

Instytut Hematologii i Transfuzjologii, Warsaw, Mazowieckie

Uniwersyteckie Centrum Kliniczne, Gdańsk, Not set

Uniwersytecki Szpital Kliniczny w Poznaniu, Poznań, Not set

Narodowy Instytut Onkologii - Oddzial w Gliwicach, Gliwice, Śląskie

Institutul Clinic Fundeni, Bucharest, Not set

Institut Català d'Oncologia (ICO) - Badalona, Badalona, Barcelona [Barcelona]

Institut Català d'Oncologia - L'Hospitalet, L'Hospitalet Del Llobregat, Barcelona [Barcelona]

Hospital Clínic de Barcelona, Barcelona, Catalunya [Cataluña]

Clinica Universidad de Navarra, Pamplona, Navarra

Hospital Universitario 12 de Octubre, Madrid, Not set

Hospital Universitario de Salamanca - Complejo Asistencial Universitario de Salamanca, Salamanca, Not set

Hospital Universitari i Politecnic La Fe, València, Not set

Local Institution - 0093, Birmingham, England

Local Institution - 0080, London, London, City Of

Local Institution - 0094, London, London, City Of

Local Institution - 0081, Glasgow, Not set

Conditions: Multiple Myeloma

Learn More ›